Skip to main content
Toggle navigation
Search
Home
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
Home
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
Type here to filter the list
(PA-376) Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Not Planned for Upfront Autologous Stem Cell Transplant: Patient Disposition and MRD Outcomes from a Prospective Clinical Trial
(PA-377) Efficacy and Safety of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-ineligible Newly Diagnosed Multiple Myeloma Patients: A Single-center Real-world Study in China
(PA-378) Steady-state Hematopoietic Cell Mobilization for Newly Diagnosed Multiple Myeloma Patients Receiving Daratumumab-based Induction Therapy versus Imid-based Induction Therapy: A Real- world Experience
(PA-379) Health-related Quality of Life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone
(PA-381) Severe Infections in Newly Diagnosed Multiple Mieloma Patients Treated Frontline with Bortezomib, Lenalidomide and Dexamethasone (VRD) in Four Reference Centers
(PA-382) Frailty and Social Deprivation Affect Real-world Outcomes in Multiple Myeloma (MM) – an England-wide Cohort Study from the UNCOVER Study Group and UKMRA Frailty Group
(PA-383) HSPA9 Contributes to Tumor Progression and Ferroptosis Resistance by Enhancing USP14-Driven xCT Deubiquitination in Multiple Myeloma
(PA-384) Impact of CD34+ Cell Infusion Dose on Immune Reconstitution and Survival in Multiple Myeloma After Autologous Stem Cell Transplantation
(PA-385) Prognostic Value of 1p Deletion in Newly Diagnosed Multiple Myeloma Patients: A Nationwide Multicenter Cohort Study by the Korean Multiple Myeloma Working Party (KMM2306)
(PA-386) Daratumumab, Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance in Transplant-eligible Multiple Myeloma Patients: Overall Survival Comparison with the CASSIOPEIA Trial
(PA-387) Importance of Re-induction in Patients with Transplant Eligible Multiple Myeloma Refractory to Frontline Therapy
(PA-388) Predicting Multiple Myeloma Mortality Using Long Short-term Memory Networks (LSTM)
(PA-389) Uncovering Hidden Prognostic Patterns in Multiple Myeloma: A Novel Unsupervised Deep-learning Method for Risk Factor Discovery
(PA-390) Validation of a Simplified Prognostic Score for Transplant-Ineligible Multiple Myeloma Patients in a Portuguese Cohort: A Real-World Analysis Based on the Greek Myeloma Study Group Model - MEPS
(PA-391) The Novel High-risk Multiple Myeloma IMS/IMWG Criteria Identify Previously Overlooked Newly-diagnosed Patients with Poor Prognosis: Validation and Real-world Application
(PA-392) Temporal Trends in Multiple Myeloma Mortality in Ecuador, 2010 – 2022: A Nationwide Joinpoint Analysis
(PA-393) Propensity Score–Weighted Comparison of Daratumumab-Rd versus Daratumumab-VMP, Rd, and VMP in High-Risk Multiple Myeloma: Insights from the MAIA and ALCYONE Trials
(PA-394) Propensity Score–Matched Comparison of Daratumumab–Rd versus Daratumumab–VMP in Transplant-Ineligible Multiple Myeloma Patients with del(17p13): An Analysis of the MAIA and ALCYONE Trials
(PA-395) Race, Lenalidomide Dosing, and Survival in Newly Diagnosed Transplantation-Ineligible Multiple Myeloma Patients
(PA-396) Patient Characteristics, Healthcare Utilization and Costs in Multiple Myeloma by Treatment Class Exposure – A German Claims Data Study
(PA-397) Effects of Two Bortezomib-Based Protocols (VCD and VRD) on Responses and Survival as Induction Treatment of Patients with Multiple Myeloma Eligible for Autologous Stem Cell Transplantation
(PA-398) Overview of First-Line Treatment of Multiple Myeloma Patients from Two Hematology Centers in Slovakia – Data from the RMG Registry
(PA-399) Survival Outcomes and Safety of High-dose Melphalan with Autologous Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study
(PA-401) Intensified Cyclophosphamide, Bortezomib, Dexamethasone (iCyBorD) for the treatment of newly diagnosed Multiple Myeloma with Acute Kidney Injury
(PA-402) Incidence and Timing of Infections in Patients with Newly Diagnosed Myeloma Treated with Contemporary Regimens
(PA-403) Predictors of High-Risk and Ultra High-Risk Multiple Myeloma from the Australia & New Zealand Myeloma and Related Diseases Registry (MRDR).
(PA-404) A Randomized Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (KRd) with Elotuzumab-KRd in Transplant-eligible Patients with Newly Diagnosed Myeloma: Initial Results for 3-year PFS and OS
(PA-405) Nuanced Treatment Decision for Newly Diagnosed Multiple Myeloma Patients Between 65-75 Years Old
(PA-406) Efficacy and Safety of Bortezomib, Pomalidomide and Dexamethasone (VPD) in Newly Diagnosed Multiple Myeloma: Single-arm, Phase-II Investigator Initiated Prospective Clinical Trial
(PA-407) Prognostic Subgroups in Hyperdiploid Myeloma and the Role of Modern Treatments
(PA-408) Long-term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma in the Era of Quadruplets
(PA-409) Real-World Experience with Daratumumab Maintenance After ASCT in Newly Diagnosed Multiple Myeloma (NDMM): Preliminary Data From a Single-Center
(PA-410) Cytarabine Plus G-CSF as Second Attempt in Very Poor Mobilizer Myeloma Patients After Cyclophosphamide Plus G-CSF and Plerixafor: Efficacy of Peripheral Blood Stem Cell (PBSC) Collection
(PA-411) Daratumumab as Post-ASCT Maintenance in Multiple Myeloma Patients with Lenalidomide Intolerance/toxicity: Results from a Single Center over the Last 5 Years
(PA-412) Optimization of Post-autologous Hematopoietic Stem Cell Transplant (ASCT) Maintenance Therapy in Multiple Myeloma (MM): Analysis of a Single-center's Results over the Last 5 Years
(PA-413) Impact of Cumulative and Relative Dose Intensity of Bortezomib, Lenalidomide, and Dexamethasone (VRD) on Depth and Duration of Response in Newly Diagnosed Multiple Myeloma (MM)
(PA-414) Cost per Responder Model of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma
(PA-415) Definition of Transplant Ineligibility in Newly Diagnosed Multiple Myeloma: A Systematic Review
(PA-416) Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 study
(PA-417) Evaluating a Value-Based, Measurable Residual Disease (MRD) - Focused Clinical Pathway in Patients with Newly Diagnosed Multiple Myeloma
(PA-418) Mortality and Trends of Multiple Myeloma in Brazil: A 27-Year Analysis.
(PA-419) Retrospective Analysis of Newly Diagnosed Multiple Myeloma Patients with Partial or Worse Response to First-line Induction Therapy
(PA-420) Real-World (RW) Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Front-Line Daratumumab (dara) Lenalidomide (len) and Dexamethasone (dex) (DRd)
(PA-421) Treatment Accessibility, Availability, and Healthcare Costs for Multiple Myeloma in South Asian Countries
(PA-422) Frontline Bortezomib-Based Therapy and Autologous Hematopoietic Stem Cell Transplantation in Latin American Multiple Myeloma Patients: Insights from a Real-World Multinational Cohort
(PA-423) HIV and Multiple Myeloma: Do Patients Present at a Younger Age? A Perspective From a South African Orthopaedic Oncology Unit.
(PA-424) Daratumumab(Dara) Lenalidomide(R) Maintenance Following Dara-Carfilzomib(K)R Dexamethasone with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Update of the Phase 2 Study IFM 2018-04
(PA-425) Enhancing GAH Score to Optimize Tolerance to Quadruplet Therapies in Multiple Myeloma: A Subanalysis of the GEM2017FIT Trial
(PA-426) Geriatric Assessment in Hematology-Guided Selection for Quadruplet Therapy in Transplant-Ineligible Myeloma. A post hoc analysis from GEM2017FIT trial
(PA-427) Optimizing the Alcyone Trial: Efficacy of Daratumumab and Bortezomib Maintenance in Transplant-ineligible Newly Diagnosed Multiple Myeloma Patients Post DVMP Induction, 2 Year Analysis
(PA-428) Clinico-hematological and Cytogenetic Profile of Multiple Myeloma Patients in a North Indian Tertiary Care Hospital
(PA-429) Effectiveness of Daratumumab plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd as Frontline Treatment for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Chart Review Study
(PA-430) Recent Trends in Real-World Frontline Treatment Patterns and Outcomes for Patients with Multiple Myeloma in the United States
(PA-431) Global Research Trends and Inequities in Clinical Trials in Multiple Myeloma: A Focus On South and Southeast Asia
(PA-432) Exploratory Analyses of Progression-free Survival (PFS) with Lenalidomide-bortezomib-dexamethasone (RVd) Alone/RVd+ASCT by Duffy Genotype in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM)
(PA-433) Frontline Anti-CD38 Monoclonal Antibodies in Patients with High-Risk, Newly Diagnosed Multiple Myeloma: A Meta Analysis
(PA-434) Renal Histopathologic Spectrum and Factors Associated with Reversibility of Renal Injury in Newly Diagnosed Patients of Multiple Myeloma
(PA-435) Survival Impact of Anti-CD38-Based Quadruplet Regimens in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis and Reconstructed Individual Patient Data Meta-Analysis
(PA-436) A Network Meta-Analysis of Randomized Clinical Trials Comparing the Efficacy of Daratumumab Versus Isatuximab in the Treatment of Multiple Myeloma
(PA-437) Real-World Evaluation of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) Induction Followed by Daratumumab and Lenalidomide (DR) Maintenance in Transplant-Eligible Multiple Myeloma
(PA-438) Pan-Pacific Multiple Myeloma (MM) Working Group Guidelines and Recommendations for CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed MM
(PA-439) Model-based Assessment of Monthly Isatuximab Dosing Performance in Newly Diagnosed Multiple Myeloma Patients Using IMROZ Phase 3 Data
(PA-440) Infusional Chemotherapy Regimens for Multiple Myeloma: Characterization of Current-day Use at a Single Center
(PA-441) Early Treatment with Daratumumab in Patients with Multiple Myeloma and Kidney Impairment: A Real-world Analysis
(PA-442) Outcomes and Maintenance Strategies for Transplant-Eligible Newly Diagnosed Multiple Myeloma Among Patients Age 40 and Younger
(PA-443) Lenalidomide Duration during Induction Does Not Affect Stem Cell Mobilisation, A Real-World Study with G-CSF and Pre-emptive Plerixafor
(PA-444) Evaluation of Haematopoietic Second Primary Malignancies in Multiple Myeloma: A Single Centre Australian Experience
(PA-445) DKRD vs. DVRD Induction Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
(PA-446) DVRD Induction Followed by Autologous Hematopoietic Stem Cell Transplantation for Older Patients with Multiple Myeloma
(PA-447) Outcomes of Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant Following VRD or KRD Induction Therapy
(PA-448) Survival of Light-chain Multiple Myeloma at the National Cancer Institute of Peru
(PA-449) Survival of IgA Multiple Myeloma at the National Cancer Institute of Peru
(PA-450) Survival of Non-transplanted Newly Diagnosed Multiple Myeloma Patients at the National Cancer Institute of Peru
(PA-451) Evaluating Racial and Ethnic Disparities in Progression Assessment Patterns in Routine Clinical Practice Among Patients with Newly Diagnosed Multiple Myeloma
(PA-452) Interim Analysis of DARA VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT as First Line in China
(PA-453) Efficacy of Daratumumab-bortezomib-lenalidomide-dexamethasone (DVRd) vs Daratumumab-lenalidomide-dexamethasone (DRd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
(PA-454) Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Newly Diagnosed Multiple Myeloma: Outcome and Safety Profile from a Multi-center Real-world Experience
(PA-455) Dara-VCd in Newly Diagnosed Multiple Myeloma with Severe Renal Impairment: A Prospective Multicenter Single-Arm Study
(PA-456) Treatment Outcomes in Isolated Gain1q Multiple Myeloma Patients
(PA-457) Early Identification of Patients with Multiple Myeloma Progressing within a Short-Term following Tandem Transplantation
(PA-458) Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation on the Treatment of Multiple Myeloma: A Single-center Clinical Analysis on PFS
(PA-459) Efficacy and Safety of Ixazomib-Based Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients: A Retrospective Analysis
(PA-460) Efficacy and Safety of Biweekly/Weekly Ixazomib-Dexamethasone Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma: A Multi-center Study
(PA-461) Selinexor Combined Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma with High-risk Cytogenetics Abnormalities: A Single-arm, Multi-center, Observational Clinical Study
(PA-527) Population Pharmacokinetic Model-Based Melphalan Dosing with Siltuximab Interleukin-6 Blockade in Older Multiple Myeloma Patients Undergoing AHCT: Phase II Run-In Results
